Comfort Care with Morphine

Introduction to Comfort Care

The primary goal of comfort care is symptom management rather than maintaining specific vital signs, and morphine is a first-line medication for this purpose, particularly for relief of dyspnea, pain control, and anxiety reduction, as recommended by the Intensive Care Medicine guidelines 1

The recommended dose of morphine in comfort care settings should be titrated to symptom relief, with no specified upper limit, according to the Intensive Care Medicine guidelines 1
Normal oxygen saturation should not be a barrier to appropriate symptom management with opioids, and oxygen levels are irrelevant if the patient appears comfortable, as stated by the British Thoracic Society guidelines 2

Low-dose morphine can be safely administered to patients with respiratory conditions without causing significant oxygen desaturation, and clinically significant respiratory depression is uncommon with doses used to treat dyspnea, as reported by the British Thoracic Society guidelines 2
Clinically significant respiratory depression is uncommon with doses used to treat dyspnea, even in elderly patients, as reported by the American Thoracic Society and National Comprehensive Cancer Network 3, 4

Opioid doses should not be reduced solely for decreased blood pressure, respiration rate, or level of consciousness when necessary for symptom management, and the dose can be safely increased if symptoms persist, as recommended by the British Thoracic Society guidelines and National Comprehensive Cancer Network 2, 5
Titration of opioids should be done slowly based on symptom response, as recommended by Intensive Care Medicine 6

The primary treatment for dyspnea should focus on optimizing management of the underlying disease, followed by opioids for refractory symptoms when other measures fail, as recommended by the American Thoracic Society 3
A systematic approach to identify the cause of dyspnea is essential, including evaluating for underlying causes such as cardiopulmonary conditions, pleural effusions, infections, anemia, and neuromuscular weakness, as recommended by the American Thoracic Society and National Comprehensive Cancer Network 3, 5

For asthma/COPD, optimizing inhaled bronchodilators and corticosteroids is recommended, as suggested by the American Thoracic Society 3
For heart failure, optimizing diuretics and afterload reduction is recommended, as suggested by the American Thoracic Society 3
For pleural effusions, considering thoracentesis and pleurodesis or drainage procedure for recurrent effusions is recommended, as suggested by the American Society of Clinical Oncology 7
For anemia, blood transfusion may be appropriate, as suggested by the American Thoracic Society 3
For infections, appropriate antimicrobial therapy is recommended, as suggested by the American Thoracic Society 3

Opioids are recommended as first-line pharmacological therapy for refractory dyspnea, with starting doses of 2.5-5 mg orally every 4 hours for opioid-naïve patients, as recommended by the American Thoracic Society, National Comprehensive Cancer Network, and Annals of Oncology 3, 8, 4
Benzodiazepines may be added when dyspnea is associated with anxiety, but are not recommended as monotherapy, as suggested by the National Comprehensive Cancer Network 5, 6
Providing supplemental oxygen for patients with hypoxemia may be beneficial, even in non-hypoxemic patients with advanced heart or lung disease, as suggested by the American Thoracic Society and Intensive Care Medicine 3, 6

Non-pharmacological interventions, including positioning, cooling the face, breathing techniques, relaxation training, respiratory training, and use of walking aids, should be implemented before starting pharmacological treatments, as suggested by the Annals of Oncology 8
Heliox may help in obstructive lung disease, but there are no studies on long-term use, as reported by the American Thoracic Society 3

Starting with low doses of opioids, such as morphine 2.5-5 mg orally every 4 hours or 1-2.5 mg subcutaneously, is recommended, as suggested by the Annals of Oncology 8
For opioid-tolerant patients, increasing the current dose by 25-50% is recommended, as suggested by the National Comprehensive Cancer Network and Annals of Oncology 5, 8
For patients with renal insufficiency, morphine should be avoided, and hydromorphone or fentanyl with adjusted dosing should be considered, as suggested by the Annals of Oncology 8
Common side effects of opioids include nausea, constipation, and drowsiness, as reported by the Journal of Clinical Oncology 7
Appropriate use of opioids for dyspnea has not been shown to hasten death, as reported by the American Journal of Respiratory and Critical Care Medicine 4